BOSTON--(BUSINESS WIRE)--Centrexion Therapeutics, a company focused on advancing the treatment of chronic pain with one of the largest exclusively pain-focused pipelines of non-opioid therapies in active development, today announced its participation in the 19th Annual BIO CEO & Investor Conference taking place February 13-14 at the Waldorf Astoria hotel in New York City.
- Monday, February 13, 2017 at 10:15 a.m. ET - Centrexion Therapeutics company presentation
- Monday, February 13, 2017 at 1:30 p.m. ET - Jeffery B. Kindler, CEO of Centrexion Therapeutics, will participate on a panel entitled “Next Generation Pain Control: Beyond Opioids”
Notably, Centrexion Therapeutics will be recognized at the conference as a Buzz of BIO winner in the “Private Therapeutics Biotech” category. Nominated and selected by an online vote, the winners are recognized as innovative and “buzzworthy” companies at the conference.
About Centrexion Therapeutics
Centrexion Therapeutics, Corp. is focused on advancing the treatment of chronic moderate to severe pain with one of the largest exclusively pain-focused pipelines of non-opioid therapies in active development. Centrexion Therapeutics recognizes the needs of over a quarter of a billion patients living with chronic pain worldwide, and aims to develop new, safer and more effective therapies that overcome the limitations and challenges associated with current pain treatments. Founded by world-renowned leaders in drug development and well-funded by key investors, Centrexion Therapeutics is building a pain treatment powerhouse to address the substantial and growing global chronic pain epidemic. Centrexion Therapeutics has recently relocated from Baltimore, Md. to Boston, Mass.
For more information about Centrexion Therapeutics, visit http://www.centrexion.com.